Switch to:
Also traded in: Australia, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt 2.96
SSH's Cash to Debt is ranked higher than
52% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. SSH: 2.96 )
Ranked among companies with meaningful Cash to Debt only.
SSH' s Cash to Debt Range Over the Past 10 Years
Min: 2.96  Med: 10000.00 Max: No Debt
Current: 2.96
Interest Coverage N/A
SSH's Interest Coverage is ranked higher than
79% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 53.44 vs. SSH: N/A )
Ranked among companies with meaningful Interest Coverage only.
SSH' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: N/A
F-Score: 1
Z-Score: -10.93
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -10999.15
SSH's Operating margin (%) is ranked lower than
97% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. SSH: -10999.15 )
Ranked among companies with meaningful Operating margin (%) only.
SSH' s Operating margin (%) Range Over the Past 10 Years
Min: -43996.61  Med: -2186.45 Max: -358.24
Current: -10999.15
-43996.61
-358.24
Net-margin (%) -11263.98
SSH's Net-margin (%) is ranked lower than
97% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. SSH: -11263.98 )
Ranked among companies with meaningful Net-margin (%) only.
SSH' s Net-margin (%) Range Over the Past 10 Years
Min: -45055.93  Med: -2186.45 Max: -358.24
Current: -11263.98
-45055.93
-358.24
ROE (%) -116.17
SSH's ROE (%) is ranked lower than
94% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 1.52 vs. SSH: -116.17 )
Ranked among companies with meaningful ROE (%) only.
SSH' s ROE (%) Range Over the Past 10 Years
Min: -238.68  Med: -122.75 Max: -63.22
Current: -116.17
-238.68
-63.22
ROA (%) -83.06
SSH's ROA (%) is ranked lower than
90% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: -0.71 vs. SSH: -83.06 )
Ranked among companies with meaningful ROA (%) only.
SSH' s ROA (%) Range Over the Past 10 Years
Min: -216.94  Med: -110.93 Max: -58.42
Current: -83.06
-216.94
-58.42
ROC (Joel Greenblatt) (%) -4266.60
SSH's ROC (Joel Greenblatt) (%) is ranked lower than
93% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. SSH: -4266.60 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SSH' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4851.22  Med: -3243.29 Max: -774.91
Current: -4266.6
-4851.22
-774.91
EBITDA Growth (3Y)(%) -12.30
SSH's EBITDA Growth (3Y)(%) is ranked lower than
72% of the 194 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. SSH: -12.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SSH' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -13.80 Max: 415.7
Current: -12.3
0
415.7
EPS Growth (3Y)(%) -9.50
SSH's EPS Growth (3Y)(%) is ranked lower than
67% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 2.60 vs. SSH: -9.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SSH' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -13.70 Max: 422.3
Current: -9.5
0
422.3
» SSH's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

SSH Guru Trades in

SSH Guru Trades in

SSH Guru Trades in

Q4 2015

SSH Guru Trades in Q4 2015

Jim Simons 36,100 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with SSH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.07
SSH's P/B is ranked higher than
87% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 2.93 vs. SSH: 1.07 )
Ranked among companies with meaningful P/B only.
SSH' s P/B Range Over the Past 10 Years
Min: 1.04  Med: 2.47 Max: 3.67
Current: 1.07
1.04
3.67
P/S 236.66
SSH's P/S is ranked lower than
98% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 3.18 vs. SSH: 236.66 )
Ranked among companies with meaningful P/S only.
SSH' s P/S Range Over the Past 10 Years
Min: 140.77  Med: 438.34 Max: 2390
Current: 236.66
140.77
2390
EV-to-EBIT 0.12
SSH's EV-to-EBIT is ranked higher than
99% of the 160 Companies
in the Global Medical Devices industry.

( Industry Median: 21.14 vs. SSH: 0.12 )
Ranked among companies with meaningful EV-to-EBIT only.
SSH' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.6  Med: -1.80 Max: 0.12
Current: 0.12
-4.6
0.12
EV-to-EBITDA 0.12
SSH's EV-to-EBITDA is ranked higher than
99% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 17.32 vs. SSH: 0.12 )
Ranked among companies with meaningful EV-to-EBITDA only.
SSH' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.7  Med: -1.80 Max: 0.12
Current: 0.12
-4.7
0.12
Current Ratio 2.94
SSH's Current Ratio is ranked higher than
52% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.86 vs. SSH: 2.94 )
Ranked among companies with meaningful Current Ratio only.
SSH' s Current Ratio Range Over the Past 10 Years
Min: 2.94  Med: 10.04 Max: 40.76
Current: 2.94
2.94
40.76
Quick Ratio 2.94
SSH's Quick Ratio is ranked higher than
64% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. SSH: 2.94 )
Ranked among companies with meaningful Quick Ratio only.
SSH' s Quick Ratio Range Over the Past 10 Years
Min: 2.94  Med: 10.04 Max: 40.76
Current: 2.94
2.94
40.76

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.22
SSH's Price/Net Cash is ranked higher than
98% of the 107 Companies
in the Global Medical Devices industry.

( Industry Median: 15.00 vs. SSH: 1.22 )
Ranked among companies with meaningful Price/Net Cash only.
SSH' s Price/Net Cash Range Over the Past 10 Years
Min: 2.33  Med: 2.89 Max: 4.65
Current: 1.22
2.33
4.65
Price/Net Current Asset Value 1.16
SSH's Price/Net Current Asset Value is ranked higher than
96% of the 215 Companies
in the Global Medical Devices industry.

( Industry Median: 6.20 vs. SSH: 1.16 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SSH' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.21  Med: 2.86 Max: 4.54
Current: 1.16
2.21
4.54
Price/Tangible Book 1.08
SSH's Price/Tangible Book is ranked higher than
91% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 3.89 vs. SSH: 1.08 )
Ranked among companies with meaningful Price/Tangible Book only.
SSH' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.03  Med: 2.81 Max: 4.37
Current: 1.08
2.03
4.37
Price/Median PS Value 0.54
SSH's Price/Median PS Value is ranked higher than
86% of the 246 Companies
in the Global Medical Devices industry.

( Industry Median: 1.04 vs. SSH: 0.54 )
Ranked among companies with meaningful Price/Median PS Value only.
SSH' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.59  Med: 1.00 Max: 4.32
Current: 0.54
0.59
4.32
Earnings Yield (Greenblatt) (%) 1201.27
SSH's Earnings Yield (Greenblatt) (%) is ranked higher than
100% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. SSH: 1201.27 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SSH' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 923.2  Med: 1362.00 Max: 4071.1
Current: 1201.27
923.2
4071.1

More Statistics

Revenue(Mil) $0
EPS $ -1.47
Beta1.44
Short Percentage of Float4.64%
52-Week Range $0.56 - 4.54
Shares Outstanding(Mil)18.36

Analyst Estimate

Dec16
Revenue(Mil)
EPS($) -1.05
EPS without NRI($) -1.05

Business Description

Industry: Medical Devices » Medical Devices
Compare:XPAR:EMG, LSE:MED, XPAR:IMPL, NAS:AMDA, XBRU:EZBG, OSTO:STIL » details
Traded in other countries:SHC.Australia, 22S.Germany,
Sunshine Heart Inc was incorporated in Delaware on August 22, 2002. The company is an early-stage medical device company engaged in developing, manufacturing and commercializing its C-Pulse Heart Assist System for treatment of Class III and ambulatory Class IV heart failure. Its C-Pulse Heart Assist System utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. It is in the process of obtaining regulatory approvals necessary to sell its product. Combined, these potential benefits may help reverse the heart failure process or maintain the patient's current condition, thereby potentially preventing the need for later-stage heart failure devices, such as LVADs, artificial hearts or transplants. Its competitors include: AbioMed, Inc., Berlin Heart GmbH, CardioKinetix, Inc., CircuLite, Inc. & HeartWare International Inc. Its business is subject to extensive federal and state government regulation.
» More Articles for SSH

Headlines

Articles On GuruFocus.com

More From Other Websites
Sunshine Heart to Release First Quarter 2016 Results on May 3, 2016 Apr 27 2016
Sunshine Heart to Release First Quarter 2016 Results on May 3, 2016 Apr 27 2016
Edited Transcript of SSH earnings conference call or presentation 3-Mar-16 2:00pm GMT Apr 08 2016
SUNSHINE HEART, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Mar 25 2016
SUNSHINE HEART, INC. Financials Mar 19 2016
SUNSHINE HEART, INC. Files SEC form 10-K, Annual Report Mar 15 2016
SUNSHINE HEART, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Mar 08 2016
Sunshine Heart to Present at the Cowen and Company 36th Annual Health Care Conference on March 8,... Mar 07 2016
Q4 2015 Sunshine Heart Inc Earnings Release - Before Market Open Mar 03 2016
SUNSHINE HEART, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation... Mar 03 2016
Sunshine Heart reports 4Q loss Mar 03 2016
Sunshine Heart reports 4Q loss Mar 03 2016
Sunshine Heart Announces Fourth Quarter and Twelve Months 2015 Financial Results and Provides... Mar 03 2016
SUNSHINE HEART, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD... Mar 02 2016
Sunshine Heart Announces the Appointment of John Erb as Its Chief Executive Officer Mar 02 2016
Sunshine Heart to Present at the Cowen and Company 36th Annual Health Care Conference on March 8,... Feb 29 2016
Sunshine Heart to Release Fourth Quarter and Year-End 2015 Results on March 3, 2016 Feb 25 2016
Sunshine Heart Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Jan 19 2016
Edited Transcript of SSH earnings conference call or presentation 3-Nov-15 2:00pm GMT Jan 07 2016
Sunshine Heart Appoints Eric Lovett as Vice President, Clinical Affairs Jan 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK